Archive · 7 Jan 2026
Doctors Raise Concerns Over Mounjaro Weightloss Drug Promotion
Doctors are worried about the way a new weight-loss drug called Mounjaro is being sold.
The drug, made by a company called Eli Lilly, is meant to help people with diabetes and long-term weight issues.
But some doctors say it's being promoted by people who aren't qualified, like on social media and billboards.
They think this is not a good way to sell a serious medicine.
The drug has been selling a lot, but the doctors are concerned that it might be used for cosmetic weight loss instead of its intended purpose.
They want the government to do something about this.
Mounjaro, a weight-loss and diabetes drug by Eli Lilly, saw sales of over ₹100 crore in December 2025, marking three consecutive months of high sales.
Doctors acknowledge the good science behind Mounjaro and similar drugs but express concerns over their promotion and potential misuse.
Dr. Rajiv Kovil, a senior diabetologist, alleges that Mounjaro is being promoted by unqualified people through social media and billboards, leading to a disparity between prescriptions and sales.
Experts emphasize that Mounjaro should only be prescribed by qualified experts for chronic weight management, not for cosmetic weight loss.
Eli Lilly has been contacted for a response regarding the increased sales and concerns raised by doctors.
- Who
- Doctors and medical practitioners
- What
- Concerns over the promotion and misuse of Mounjaro, a weight-loss and diabetes drug
- When
- Reported on January 6, 2026, with sales data from December 2025
- Where
- India
- Why
- Due to the spike in sales and concerns over unqualified promotion and misuse of the drug
- Drug Name
- Mounjaro
- Company
- Eli Lilly
- December 2025 Sales
- ₹105 crore
- Total Sales (as of December 2025)
- ₹601 crore
- Primary Use
- Diabetes and chronic weight management
- Concerns Raised
- Misuse and unqualified promotion
- Date of Report
- January 6, 2026
